BioRadar Blog
Biotech trading insights, PDUFA analysis, and market intelligence.
Biotech Conference Season 2026: Which Events Move Stocks the Most
Biotech conferences are where companies present clinical data for the first time, announce partnerships, and reveal pipeline updates. For traders, conference season creates some of the most predictable volatility windows…
Read article →Insider Trading in Biotech: What SEC Form 4 Filings Really Tell You
When a biotech CEO buys shares of their own company with personal money before a major catalyst, it is one of the strongest bullish signals in the entire market. Insider…
Read article →Understanding Drug Pipelines: How to Evaluate a Biotech Company Like an Analyst
A biotech company is only as valuable as its drug pipeline. Unlike traditional companies valued on revenue and earnings, biotech valuations are driven by the probability-weighted value of drugs in…
Read article →Short Squeeze Setups in Biotech: How to Spot Them Before They Explode
Biotech short squeezes are among the most explosive moves in the stock market. When a heavily shorted stock gets a positive catalyst — FDA approval, strong trial data, or a…
Read article →How to Read Biotech Cash Runway: The #1 Signal That Predicts Dilution
In biotech investing, cash runway is the single most important metric that separates winners from dilution traps. Unlike revenue-generating companies, most biotech firms burn cash every quarter while waiting for…
Read article →Best PDUFA Dates Q2 2026: FDA Approval Catalysts Every Biotech Trader Must Watch
PDUFA (Prescription Drug User Fee Act) dates are the single most important catalysts in biotech trading. These are the deadlines by which the FDA must make approval decisions on new…
Read article →